2009 Press Releases
Onyx Pharmaceuticals Announces A Teleconference And Webcast To Provide An Update On Nexavar
EMERYVILLE, Calif. — Apr. 26, 2009
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a teleconference and webcast on Monday, April 27, 2009, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to provide an update on Nexavar® (sorafenib) tablets.
Interested parties may access a live webcast of the presentation on the company's website at:
or by dialing 847-413-3238 and using the passcode 24429530. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 24429530 approximately one hour after the teleconference concludes. The replay will be available through May 27, 2009.
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated®. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at www.onyx-pharm.com.
Nexavar® (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.